Modis Therapeutics
Therapeutics for Orphan Diseases

Modis is a biopharmaceutical company focused on developing therapies for mitochondrial DNA depletion disorders. The company’s lead program is currently in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease that has no current treatment options and is often fatal.


University
Columbia University
Sector
Life Science
Status
Active
Initial Investment Stage
Early
View Website